Third. by Cuicui Liu (1496260)

“…However, following the epidemic, as the economy has not yet fully recovered, the multifinance sector is more likely to experience spillover risks from other sectors, and the insurance sector also primarily acts as a risk spillover. …”

Intraoperative facial and intraoral photographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

Posttreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

JHMV N1347A has decreased replication in the olfactory bulbs of mice. by Catherine M. Kerr (21492574)

LuxR G37V has decreased DNA-binding activity. by Chelsea A. Simpson (9579303)

Validation of child labor measures using third-party data, households with all children in school. by Guilherme Lichand (11410286)

Superimposition of the cephalometric tracings obtained before and after treatment of case with mandibular third molar extraction. by Lijuan Liu (136685)

Comparison of pretreatment cephalometric variables between premolar extraction and mandibular third molar extraction groups. by Lijuan Liu (136685)

Comparison of upper and lower arch crowding between premolar extraction group and the mandibular third molar extraction groups. by Lijuan Liu (136685)

Comparison of treatment effects between premolar extraction and mandibular third molar extraction groups. * p < 0.05; ** p < 0.01. by Lijuan Liu (136685)

Dynamics of net spillage in the third stage (post epidemic). by Cuicui Liu (1496260)

Changes in total spillage during the third stage (post epidemic). by Cuicui Liu (1496260)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”

NANOG has glycosylation sites. by Yin Tian (181303)

Training-induced changes in bipedal stance. by Cristina Dolciotti (16317330)

Consolidation of training-induced changes in unipedal stance: 95% Area, Y Sway Amplitude and LFS. by Cristina Dolciotti (16317330)

Consolidation of training-induced changes in unipedal stance: Path Length, X Sway Amplitude and Velocity. by Cristina Dolciotti (16317330)